|本期目录/Table of Contents|

[1]刘艳华,杨 彤,兰 杨,等.多柔比星联合达沙替尼协同抗肿瘤细胞活性的研[J].宁夏医科大学学报,2018,(08):881-884,890.[doi:10.16050/j.cnki.issn1674-6309.2018.08.003]
 LIU Yanhua,YANG Tong,LAN Yan,et al.Synergistic Anti-tumor Effects of Doxorubicin Combined with Dasatinib[J].Ningxia Medical University,2018,(08):881-884,890.[doi:10.16050/j.cnki.issn1674-6309.2018.08.003]
点击复制

多柔比星联合达沙替尼协同抗肿瘤细胞活性的研(PDF)
分享到:

《宁夏医科大学学报》[ISSN:1005-8486/CN:64-1029/R]

卷:
期数:
2018年08期
页码:
881-884,890
栏目:
论著
出版日期:
2018-08-30

文章信息/Info

Title:
Synergistic Anti-tumor Effects of Doxorubicin Combined with Dasatinib
文章编号:
1674-6309(2018)08-0881-04
作者:
刘艳华 杨 彤 兰 杨 曹爱晨
(宁夏医科大学药学院, 银川 750004)
Author(s):
LIU Yanhua YANG Tong LAN Yan CAO Aichen
(College of Pharmacy, Ningxia Medical University, Yinchuan 750004)
关键词:
多柔比星达沙替尼联合用药细胞毒性协同作用
Keywords:
doxorubicin dasatinib combination therapycytotoxicity synergistic effect
分类号:
R943.42;R979.1
DOI:
10.16050/j.cnki.issn1674-6309.2018.08.003
文献标志码:
A
摘要:
目的 研究多柔比星与达沙替尼联合用药,抑制肿瘤细胞增殖的协同抗肿瘤活性。方法 采用 MTT 法研究多柔比星、达沙替尼单用以及两者联合用药分别对小鼠转移性乳腺癌4T1.2细胞株、人前列腺癌PC3细胞株、人肝癌HepG2细胞株、人结肠癌HCT-116细胞株的细胞增殖抑制率,并计算出相应的半数抑制浓度值及联用指数,评价多柔比星和达沙替尼的抗肿瘤活性和其联合用药的协同作用。结果 多柔比星和达沙替尼联合用药抑制4T1.2、PC3、HepG2和HCT-116细胞增殖显著强于多柔比星和达沙替尼分别单用抑制细胞增殖的作用。多柔比星和达沙替尼联合用于4T1.2和PC3细胞的联用指数最低,具有高度的协同效应。结论 多柔比星与达沙替尼联用,具有高效抑制4T1.2、PC3、HepG2和HCT-116肿瘤细胞增殖的协同作用。
Abstract:
Objective To study the synergistic anti-tumor effects of doxorubicin combined with dasatinib. Methods MTT assay was used to study the inhibitory rate of cell proliferation of mouse metastatic breast cancer cell line 4T1.2,human prostate cancer cell line PC3,human liver cancer HepG2 cell line and human colon cancer HCT-116 cell line by doxorubicin, dasartinib alone and doxorubicin combined with dasartinib, and the corresponding half inhibitory concentration was calculated. The antitumor activity of doxorubicin and dasartinib and the synergistic effect of their combination were evaluated. Results The proliferation inhibition of doxorubicin and dasatinib combo against 4T1.2,PC3,HepG2 and HCT-116 cell lines was more active than doxorubicin and dasatinib treated alone. The combination of doxorubicin and dasatinib treated against 4T1.2 and PC3 cells showed stronger synergy effect on proliferation inhibition. Conclusion Doxorubicin combining with dasatinib showed significant synergistic effect on tumor cell proliferation effect in 4T1.2,PC3,HepG2 and HCT-116 cell lines.

参考文献/References:


[1] Lu DY,Lu TR,Yarla NS,et al. Drug combinationin clinical cancer treatments[J]. Rev Recent Clin Trials, 2017,12(3):202-211.
[2] Scher KS,Somlo G. Dasatinib: a novel therapy for breast cancer[J]. Expert Opin Investig Drugs,2013, 22(6):795-801.
[3] Araujo J,Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors [J]. Cancer Treat Rev,2010,36(6): 492-500.
[4] Lei QH,Tian QW,Sheng JM,et al. Unified D-α-Tocopherol 5-Fu/SAHA bioconjugates self-assemble as complex nanodrug for optimized combination therapy [J]. Nanomedicine,2018,13(11),1285-1301.
[5] Wahl DR,Lawrence TS. Integrating chemoradiation and molecularly targeted therapy[J]. Adv Drug Deliv Rev,2017,109:74-83.
[6] 胡宏祥,王学清,张华,等. 分子靶向抗肿瘤药物的作用机制及临床研究进展[J]. 药学学报,2015,50(10):1232-1239.
[7] Roskoski RJ. Src protein-tyrosine kinase structure, mechanism, and molecule inhibitors[J]. Pharmacol Res,2015,94:9-25.
[8] Secord AA,Teod D,Jia J,et al. Dasatinib(BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression [J]. Int J Gynecol Cancer,2014,24(2):218-225.
[9] Park B,Whichard ZL,Corey SJ. Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines-Lessons for design of combination targeted therapy[J]. Cancer Lett,2012,320(1):104-110.
[10] Pichot CS,Hartig SM,Xia L,et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells[J]. Br J Cancer,2009,101(1):38-47.
[11] Kemp JA,Shim MS,Heo CY,et al. “Combo” nano-medicine:co-delivery of multi-modal therapeutics for efficient,targeted,and safe cancer therapy[J]. Adv Drug Deliv Rev,2016,98:3-18.
[12] Parhi P,Mohanty C,Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy[J]. Drug Discov Today,2012,17(17-18):1044-1052.
[13] 张波,张娜. 纳米载体共递送化疗药物用于肿瘤联合治疗的研究进展[J]. 中国新药杂志,2014,23 (21):2514-2520.

相似文献/References:

[1]吕丹妮,摆志霞,陈学新.mPTP介导脂肪乳逆转布比卡因对心肌细胞能量代谢的影响[J].宁夏医科大学学报,2016,(01):21.[doi:10.16050/j.cnki.issn1674-6309.2016.01.006]
 LV Danni,BAI Zhixia,CHEN Xuexin.Effect of Lipid Emulsion Reverses Bupivacaine on Myocardial Cell Energy Metabolism Va mPTP[J].Ningxia Medical University,2016,(08):21.[doi:10.16050/j.cnki.issn1674-6309.2016.01.006]
[2]李宏辉,刘秀芳,马潇,等.辛硫磷和灭多威混配对雄性小鼠生殖细胞的毒性作用[J].宁夏医科大学学报,2009,(05):582.
 LI Hong-hui,LIU Xiu-fang,MA Xiao,et al.[J].Ningxia Medical University,2009,(08):582.
[3]师志云,杨宝珍,王立斌,等.CTLA-4基因的多态性与自身免疫性甲状腺病的相关性研究[J].宁夏医科大学学报,2010,(03):330.
 SHI Zhi-yun,YANG Bao-zhen,WANG Li-bin,et al.Study of the A/G(49)Polymorphism of CTLA-4 Gene Exon 1 in Autoimmune Thyroid Diseases[J].Ningxia Medical University,2010,(08):330.

备注/Memo

备注/Memo:
收稿日期:2018-03-10
基金项目:国家自然科学基金(81660590);宁夏回族自治区大学生创新训练计划(NXCX2015191)
作者简介:刘艳华(1983-),女,博士,研究方向:新型给药系统。 E-mail:lyanhua1214@126.com
更新日期/Last Update: 2018-08-30